Related Experiment Video
Updated: Jan 3, 2026
14:01
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
Published on: July 22, 2011
15.0K
BAY 41-2272 inhibits human T lymphocyte functions
Marina U W B Carvalho1, Paola Vendramini1, Christina Arslanian Kubo1
1Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
International Immunopharmacology
|November 17, 2019
Summary
BAY 41-2272, a stimulator of soluble guanylate cyclase (sGC), significantly inhibits human T lymphocyte functions, including interferon-gamma production and proliferation. This compound shows potential as an immunomodulatory drug for autoimmune and inflammatory conditions.
Area of Science:
- Immunology
- Pharmacology
Background:
- Soluble guanylate cyclase (sGC) stimulates cyclic guanosine monophosphate (cGMP) production.
- BAY 41-2272 is an sGC stimulator with potential therapeutic applications.
Purpose of the Study:
- To investigate the effects of BAY 41-2272 on human T lymphocyte functions.
- To assess BAY 41-2272's potential as an immunomodulatory agent.
Main Methods:
- Human T cells were pretreated with BAY 41-2272.
- T cell activation was induced using phorbol myristate acetate (PMA) or PMA/ionomycin.
- Interferon-gamma (IFN-γ) production, CD69 and T-bet expression, and T lymphocyte proliferation were measured.
Main Results:
- BAY 41-2272 significantly inhibited IFN-γ production in a dose-dependent manner.
- Suppression of CD69 and T-bet expression was observed with BAY 41-2272 treatment.
- T lymphocyte proliferation was markedly reduced by BAY 41-2272.
Conclusions:
- BAY 41-2272 demonstrates potent inhibitory effects on human T lymphocyte functions.
- The findings suggest BAY 41-2272 could be a candidate for treating autoimmune/inflammatory diseases and lymphoproliferative disorders.
